MGNX NASDAQ
MacroGenics, Inc.
1W: -30.1%
1M: -39.9%
3M: -33.5%
YTD: +51.5%
1Y: +32.6%
3Y: -49.6%
5Y: -87.5%
$2.44
+0.25 (+11.42%)
Weekly Expected Move ±21.5%
$1
$2
$2
$3
$3
Credit Risk of going bust: higher than 84% of companies Debt: 18.4% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the second-riskiest tenth, about 1 in 87 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.11 (down 96%), MacroGenics, Inc. would be worth roughly what it owes.
Total debt $35.1M against a stock market value of $155.4M.
Distance to default 2.26 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $20.0M (short-term plus half of long-term), stock volatility 92.7%; Altman Z'' -9.42. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.11 (down 96%), MacroGenics, Inc. would be worth roughly what it owes.
Total debt $35.1M against a stock market value of $155.4M.
Distance to default 2.26 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $20.0M (short-term plus half of long-term), stock volatility 92.7%; Altman Z'' -9.42. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
10 relationships9
As Filer
counterparties named
1
As Counterparty
mentioned by others
2
Rel. Types
2021-06-16
Earliest Filing
2025-06-10
Latest Filing
partner: 8
customer: 1
Counterparties (Filed by MGNX)
9 relationshipsCompanies named in MGNX's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Sagard Healthcare Partners | — | partner | Acquired royalty rights on ZYNYZ global net sales from MacroGenics, Inc. | 2025-06-10 | View |
| Incyte Corporation | INCY | partner | Original licensor of ZYNYZ under the Global Collaboration and License Agreement. | 2025-06-10 | View |
| DRI Healthcare Acquisitions LP | — | customer | Purchased a single-digit royalty interest on global net sales of TZIELD from MacroGenics, Inc. | 2023-03-09 | View |
| DRI Healthcare Trust | — | partner | Parent company of DRI Healthcare Acquisitions LP, the counterparty in the royalty purchase agreement. | 2023-03-09 | View |
| Provention Bio | — | partner | Original counterparty to the Asset Purchase Agreement under which the TZIELD royalty interest was held by MacroGenics, I | 2023-03-09 | View |
| ARE-Maryland No. 45, LLC | — | partner | Landlord for lease amendment extending term to 2035 | 2022-12-16 | View |
| Gilead Sciences, Inc. | GILD | partner | Exclusive option and collaboration agreement to develop MGD024 and two additional bispecific research programs. | 2022-10-17 | View |
| Zai Lab US LLC | ZLAB | partner | Collaboration and license agreement for bispecific antibody development and commercialization | 2021-06-16 | View |
| Zai Lab Limited | ZLAB | partner | Previous collaborator for regional development rights in Asia | 2021-06-16 | View |
Mentioned As Counterparty
1 mentionsOther companies that named MGNX in their SEC 8-K filings.
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-23 | Other Events; Exhibits | View | |
| 2026-09-03 | Exhibits | View | |
| 2026-08-13 | Earnings Release; Exhibits | View | |
| 2026-07-23 | Other Events | View | |
| 2026-07-08 | Officer/Director Change | View | |
| 2026-07-07 | Acquisition/Disposition; Regulation FD; Exhibits | Acquisition | View |
| 2026-05-20 | Shareholder Vote | View | |
| 2026-05-13 | Earnings Release; Exhibits | View | |
| 2026-05-12 | Material Agreement; Regulation FD; Exhibits | Agreement | View |
| 2026-05-04 | Material Agreement; Other Events; Exhibits | Agreement | View |
| 2026-04-08 | Other Events | View | |
| 2026-03-09 | Results of Operations and Financial Condition | View | |
| 2026-03-02 | Other Events | View | |
| 2026-02-24 | Other Events | View | |
| 2025-11-20 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-11-12 | Results of Operations and Financial Condition | View | |
| 2025-08-14 | Results of Operations and Financial Condition | View | |
| 2025-08-13 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2025-06-10 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2025-05-22 | Submission of Matters to a Vote of Security Holders | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR